← Back to patent-cliff list
Linezolid intradiscal (Persica Pharmaceuticals)
Tier C — Watch / tradeLinezolid intradiscal (Persica Pharmaceuticals)
Persica Pharmaceuticals Ltd
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：50S ribosomal subunit
Indications (approved)：Low back pain
Regional status
US
-
EU
Phase II
2020-01-20
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Linezolid intradiscal (Persica Pharmaceuticals)?
Approved indications include: Low back pain.
When does the Linezolid intradiscal (Persica Pharmaceuticals) patent expire?
No public expiry year is available for Linezolid intradiscal (Persica Pharmaceuticals) yet; this page updates once verified.
How do I get a quote for Linezolid intradiscal (Persica Pharmaceuticals) intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07